Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features

Annals of Oncology

Volumn 25, Issue 10, 2014, Pages 1995-2001

  Missiaglia, E ^a   Jacobs, B ^b   D'Ario, G ^a   Di Narzo, A F ^a   Soneson, C ^a   Budinska, E ^c   Popovici, V ^c   Vecchione, L ^b   Gerster, S ^a   Yan, P ^d   Roth, A D ^e   Klingbiel, D ^a,f   Bosman, F T ^d   Delorenzi, M ^a,d,g   Tejpar, S ^b  

^a SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c MASARYK UNIVERSITY   (Czech Republic)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^g Ludwig Center for Cancer Research

Author keywords

colon cancer; expression profiling; mutations; oncogenic pathways; survival

Indexed keywords

TUMOR PROTEIN;

BIOSYNTHESIS; CANCER STAGING; COLONIC NEOPLASMS; COPY NUMBER VARIATION; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METASTASIS; MICROSATELLITE INSTABILITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; TRANSLATIONAL RESEARCH;

COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICROSATELLITE INSTABILITY; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84922536963     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu275     Document Type: Article

References (25)

1. Jass, J.R., Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50:1 (2007), 113–130.
2. Snover, D.C., Update on the serrated pathway to colorectal carcinoma. Hum Pathol 42:1 (2011), 1–10.
3. Budinska, E., Popovici, V., Tejpar, S., et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol 231:1 (2013), 63–76.
4. De Sousa, E.M.F., Wang, X., Jansen, M., et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 19:5 (2013), 614–618.
5. Marisa, L., de Reynies, A., Duval, A., et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med, 10(5), 2013, e1001453.
6. Sadanandam, A., Lyssiotis, C.A., Homicsko, K., et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 19:5 (2013), 619–625.
7. Popovici, V., Budinska, E., Tejpar, S., et al. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J Clin Oncol 30:12 (2012), 1288–1295.
8. Tian, S., Roepman, P., Popovici, V., et al. A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency. J Pathol 228:4 (2012), 586–595.
9. Sanz-Pamplona, R., Cordero, D., Berenguer, A., et al. Gene expression differences between colon and rectum tumors. Clin Cancer Res 17:23 (2011), 7303–7312.
10. Yamauchi, M., Morikawa, T., Kuchiba, A., et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 61:6 (2012), 847–854.
11. Iacopetta, B., Are there two sides to colorectal cancer?. Int J Cancer 101:5 (2002), 403–408.
12. Benedix, F., Kube, R., Meyer, F., et al. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum 53:1 (2010), 57–64.
13. Meguid, R.A., Slidell, M.B., Wolfgang, C.L., et al. Is there a difference in survival between right- versus left-sided colon cancers?. Ann Surg Oncol 15:9 (2008), 2388–2394.
14. Weiss, J.M., Pfau, P.R., O'Connor, E.S., et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results—Medicare data. J Clin Oncol 29:33 (2011), 4401–4409.
15. Sinicrope, F.A., Mahoney, M.R., Smyrk, T.C., et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol 31:29 (2013), 3664–3672.
16. Xie, T., G, D.A., Lamb, J.R., et al. A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterations. PLoS ONE, 7(7), 2012, e42001.
17. Bosman, F.T., Yan, P., Tejpar, S., et al. Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial. Clin Cancer Res 15:17 (2009), 5528–5533.
18. Cancer Genome Atlas Network, Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:7407 (2012), 330–337.
19. De Roock, W., Claes, B., Bernasconi, D., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11:8 (2010), 753–762.
20. LaPointe, L.C., Dunne, R., Brown, G.S., et al. Map of differential transcript expression in the normal human large intestine. Physiol Genomics 33:1 (2008), 50–64.
21. Rad, R., Cadinanos, J., Rad, L., et al. A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell 24:1 (2013), 15–29.
22. Burrell, R.A., McClelland, S.E., Endesfelder, D., et al. Replication stress links structural and numerical cancer chromosomal instability. Nature 494:7438 (2013), 492–496.
23. Lai, C.H., Tseng, J.T., Lee, Y.C., et al. Translational up-regulation of Aurora-A in EGFR-overexpressed cancer. J Cell Mol Med 14:6B (2010), 1520–1531.
24. Powell, A.E., Wang, Y., Li, Y., et al. The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell 149:1 (2012), 146–158.
25. Brule, S.Y., Jonker, D.J., Karapetis, C.S., et al. Location of colon cancer (right-sided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET): NCIC CTG CO.17. J Clin Oncol, 2013 abstract 31, (suppl; abstr 3528).